This may be mainly because these classical anti-inflammatory strategies may not target the noninflammatory or noncanonical effects during NLRP3 inflammasome activation in the development of NASH [6], and therefore they may only have a limited therapeutic effect. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.